Developments LENZ Therapeutics and JIXING in exclusive greater China license agreement Closely held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment... April 13, 2022